Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12874037 | 0.88 | CACNA1H (0.45) | CACNA1HCACNA1BCACNA1CP2RY14TDP1 | |
| SCHEMBL13699136 | 0.75 | RHOC (0.53) | TDP1GAAMEN1KMT2ACA1 | |
| SCHEMBL24742277 | 0.73 | SIGMAR1 (0.41) | CACNA1HCACNA1BCACNA1CP2RY14TDP1 | |
| SCHEMBL28929817 | 0.73 | HDAC1 (0.51) | P2RY14TDP1HTTMEN1KMT2A | |
| SCHEMBL19300897 | 0.73 | RHOC (0.50) | CACNA1HCACNA1BCACNA1CTDP1GAA | |
| SCHEMBL18357827 | 0.73 | CACNA1B (0.54) | CACNA1HCACNA1BCACNA1CCA1CA2 | |
| SCHEMBL18072358 | 0.72 | CACNA1H (0.43) | CACNA1HCACNA1BCACNA1CSTK17BSTK17A | |
| SCHEMBL14433656 | 0.72 | RHOC (0.48) | CACNA1HCACNA1BCACNA1CTDP1STK17B | |
| SCHEMBL8686230 | 0.71 | CACNA1H (0.46) | CACNA1HCACNA1BCACNA1CTDP1GAA | |
| SCHEMBL14454939 | 0.71 | TDP1 (0.50) | TDP1HTTSTK17BSTK17AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203459-B1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2016-03-16 | — | — | EP | disclosed |
| EP-2203459-B1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2016-03-16 | — | — | EP | disclosed |
| US-8901112-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901112-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140005184-A1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2014-01-02 | — | — | US | disclosed |
| US-8476261-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476261-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20110034436-A1 | SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2203459-A1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | Activx Biosciences, Inc. (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009035684-A1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009035684-A1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005184-A1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | GSK3A, GSK3B, GSKIP | CACNA1H 3691/4885CACNA1B 3385/4885CACNA1C 3438/4885 |
| US-20110034436-A1 | SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS | GSK3A, GSK3B, GSKIP | CACNA1H 3713/4885CACNA1B 2966/4885CACNA1C 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.